Penarth headquartered and world leading point-of-care diagnostics firm EKF has reported a surge in revenues and profits boosted by significant demand for its Covid sample collection devices.
The Alternative Investment Market listed firm saw revenues for 2021 climb 25% to £81.8m, with pre-tax profits up from £15.4m to £21.4m. While it said there will be a significant reduction in Covid-related manufacturing, it is on track to continue to expand under its latest growth plan to 2024.
Last September EKF acquired Texas-based Advanced Diagnostic Laboratory which it described as an “excellent strategic fit” within its existing diagnostics offering that will strengthen its offering to customers.
